http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Geographic Variations in the Patterns of Sensitization to Aeroallergens in Korean Adults
Min Gyu Kang,Mi-Young Kim,Su-Jung Kim,Eun-Jung Jo,Seung-Eun Lee,Woo-Jung Song,Jae-Woo Kwon,Sang-Min Lee,Chan-seon Park,Yoon-Seok Chang,Jae-Chun Lee,Young-Koo Jee,In-Seon Choi,Kyung-Up Min,Sang-Heon Ch 위기관리 이론과 실천 2017 위기관리 이론과 실천 세미나발표논문집 Vol.2018 No.-
Min Chul Kim,Jae Yeong Cho,Hae Chang Jeong,Ki Hong Lee,,Keun Ho Park,Doo Sun Sim,Nam Sik Yoon,Hyun Joo Youn,Kye Hun Kim,Young Joon Hong,Hyung Wook Park,Ju Han Kim,Myung Ho Jeong,Jeong Gwan Cho,Jong Ch 대한심장학회 2016 Korean Circulation Journal Vol.46 No.4
Background and Objectives: There is limited information on the transient or persistent no reflow phenomenon in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Subjects and Methods: The study analyzed 4329 patients with AMI from a Korean multicenter registry who underwent PCI using coronary stents (2668 ST-elevation and 1661 non-ST-elevation myocardial infarction [MI] patients): 4071 patients without any no reflow, 213 with transient no reflow (no reflow with final thrombolysis in myocardial infarction [TIMI] flow grade 3), and 45 with persistent no reflow (no reflow with final TIMI flow grade≤2). The primary endpoint was all-cause mortality during 3-year follow-up. We also analyzed the incidence of cardiac mortality, non-fatal MI, re-hospitalization due to heart failure, target vessel revascularization, and stent thrombosis. Results: The persistent no reflow group was associated with higher all-cause mortality (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.08-3.65, p=0.028) and cardiac mortality (HR 3.28, 95% CI 1.54-6.95, p=0.002) compared with the normal reflow group. Transient no reflow increased all-cause mortality only when compared with normal reflow group (HR 1.58, 95% CI 1.11-2.24, p=0.010). When comparing transient and persistent no reflow, persistent no reflow was associated with increased all-cause mortality (46.7 vs. 24.4%, log rank p=0.033). Conclusion: The persistent no reflow phenomenon was associated with a poor in-hospital outcome and increased long-term mortality mainly driven by increased cardiac mortality compared to the transient no reflow phenomenon or normal reflow.
( Jung Yoon Choi ),( Jae Kyeom Sim ),( Jee Youn Oh ),( Won Jai Jung ),( Eun Joo Lee ),( Kyoung Hun Min ),( Gyu Young Hur ),( Sung Yong Lee ),( Sang Yeub Lee ),( Je Hyeong Kim ),( Jae Jeong Shim ),( Ch 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Churg-Strauss syndrome (CSS) is a systemic small-vessel vasculitis which predominantly involves the lung, skin, gastrointestinal tract and the nervous system, but here we report a CSS case involving the mediastinal lymph node (LN) and gallbladder (GB). Case report: A 43-year-old woman with 2-year history of asthma was admitted with dyspnea and wheezing. The patient showed marked peripheral eosinophilia and multiple mediastinal lymphadenopathy with multifocal pneumonic consolidations on both lower lungs in chest computed tomography (CT). The patient was treated with methylprednisolone and antibiotics assuming asthma exacerbation with pneumonia. Following 7 days of treatment, dyspnea improved with near disappearance of pulmonary in. ltration. However, during steroid tapering, acute cholecystitis with multiple GB stones developed. Follow-up chest CT showed much improved consolidations, but no significant change of enlarged mediastinal LN. In addition, serum P-anti-neutrophil cytoplasmic antibody was positive. Because she had persistent abdominal pain requiring cholecystectomy, co-operation of cholecystectomy and concurrent wedge resection with mediastinal LN biopsy was performed for tissue confirmation. Necrotizing and granulomatous vasculitis with eosinophil in filtrates was observed in the specimens of GB, lung, and LN, respectively. Furthermore, skin biopsy was performed from purpuric lesions on both dorsum and it showed leukocytoclastic vasculitis with eosinophil predominance. finally, she was con. rmed as CSS based on asthma, eosinophilia, polyneuropathy, pulmonary in filtrates and extravascular eosinophils by biopsy confirmation on multiple sites. After 4 weeks of treatment with methylprednisolone 60mg/day, her associated symptoms and eosinophilia were improved. Conclusion: We herein report an unusual case of CSS manifested by mediastinal lymphadenopathy with lung consolidation and necrotizing eosinophilic cholecystitis, which can be misdiagnosed as pneumonia with reactive LN enlargement and stone induced cholecystitis. Thus, involvement of CSS in other organ should not be overlooked.
자궁경부암 세포주들과 Nude mouse 에 이종이식한 자궁경부암 세포에서 아데노바이러스와 리포펙틴을 이용한 종양억제 유전자 ( p53 ) 의 이입율
여경아(Kyeong A Yeo),정재은(Jae Eun Jung),이혜영(Hye Young Lee),이방현(Bang Hyon Lee),김태형(Tae Hyung Kim),천병수(Byeung Soo Cheung),노민석(Min Suk Rho),이준모(Joon Mo Lee),남궁성은(Sung Eun Namkoong),박용석(Yong Seok Park),김종국(Ch 대한산부인과학회 2001 Obstetrics & Gynecology Science Vol.44 No.6
Background: The classical treatment of the cervical cancer is surgery, radiotherapy, chemotherapy. Even though the improvement of treatment successful rate, conventional therapy has some limitations. Recent cutting edge of cancer therapy has been developed in gene level including understand the biological characteristics of the cancer cells, enhance the human immune response, suppress the cancer cell proliferation. Therefore, the gene therapy is proposed to new treatment strategy. Purpose: The transfection efficiency of cervical cancer cell lines and cervical cancer cell line xerografted nude mouse was investigated by transfection of liposome and infection of adenovirus mediated suppressor(p53) and reportor(LacZ) gene. Method: The cervical cancer cell lines was used in this study were CaSki, SiHa (HPV16 positive, wild type p53 gene), HeLa, He]aS3(HPV18 positive, wild type p53 gene) and C33A, HT3(HPV negative, mutant p53). Direct plasmide and AdCMVp53 gene transfection was performed by using liposome system (pRcCMVLacZ / lipofectin, FuGene 6, Ca-phosphate). LacZ gene was used as the reportor gene for the transfection efficiency evaluation. Expression of p53 in cell lines and tumor tissue was confirmed by western blot and immunohistochemical staining. Xenografted nude mouse of SiHa cell line was infected by AdCMVp53 and AdCMVLacZ. Transfection efficiency was observed by same as above. Results: In cervical cancer cell lines, gene transfection using liposome system(pRcCMVLacZ/lipofectin, FuGene 6, Ca-phosphate)revealed different transfection efficiency, especially pRcCMVLacZ in Fugene 6 showed 18-40% of high transfection efficiency in 6 cervical cancer cell lines by X-gal staining and AdCMVp53 showed 95-98% of the high transfection efficiency in HeLa, C33A. AdCMVp53 was significantly expressed at 2-5days after injection xenografted nude mouse on the western blot and transfection efficiency was 19.79±5.36, 26.26 ± 11.69, 14.77±3.98,15.99 ±6.43%(day1-5). AdCMVLacZ were found to immunohistochemistry analysis, in vivo transFection efficiency was 61.26±4.66, 59.63±9.12, 29.46±14.33, 31.73±22.64%(day 1-5) at ×200 and 88.68.65, 70.85±20.94, 40.75±25.44, 48.21±10.97% (day 1-5) at ×400. Conclusion: As a results , adenovirus-mediated transfection efficiency was higher in vivo experiment compared to cell lines. These high efficiency of adenovirus-mediated suppressor gene(p53) could become a significant meaningful data gene therapy strategy both transgenic mice and cervical cancer cell lines.
Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors
Achary, Raghavendra,Yun, Jeong In,Park, Chi Min,Mathi, Gangadhar Rao,Lee, Joo Yun,Ha, Jae Du,Chae, Chong Hak,Ahn, Sunjoo,Park, Chi Hoon,Lee, Chong Ock,Hwang, Jong Yeon,Yun, Chang-Soo,Jung, Hee Jung,Ch Pergamon 2016 Bioorganic & medicinal chemistry Vol.24 No.2
<P>Exploration of the two-position side chain of pyrimidine in LDK378 with tetrahydroisoquinolines (THIQs) led to discovery of 8 and 17 as highly potent ALK inhibitors. THIQs 8 and 17 showed encouraging in vitro and in vivo xenograft efficacies, comparable with those of LDK378. Although THIQ analogs (8a-o and 17a-i) prepared were not as active as their parent compounds, both 8 and 17 have significant inhibitory activities against various ALK mutant enzymes including G1202R, indicating that this series of compounds could be further optimized as useful ALK inhibitors overcoming the resistance issues found from crizotinib and LDK378. (C) 2015 Elsevier Ltd. All rights reserved.</P>
Clinical Practice Guidelines for the Endoscopic Management of Peripancreatic Fluid Collections
( Chi Hyuk Oh ),( Tae Jun Song ),( Jun Kyu Lee ),( Jin-seok Park ),( Jae Min Lee ),( Jun Hyuk Son ),( Dong Kee Jang ),( Miyoung Choi ),( Jeong-sik Byeon ),( In Seok Lee ),( Soo Teik Lee ),( Ho Soon Ch 대한소화기학회 2021 Gut and Liver Vol.15 No.5
Endoscopic ultrasonography-guided intervention has gradually become a standard treatment for peripancreatic fluid collections (PFCs). However, it is difficult to popularize the procedure in Korea because of restrictions on insurance claims regarding the use of endoscopic accessories, as well as the lack of standardized Korean clinical practice guidelines. The Korean Society of Gastrointestinal Endoscopy appointed a Task Force to develop medical guidelines by referring to the manual for clinical practice guidelines development prepared by the National Evidence-Based Healthcare Collaborating Agency. Previous studies on PFCs were searched, and certain studies were selected with the help of experts. Then, a set of key questions was selected, and treatment guidelines were systematically reviewed. Answers to these questions and recommendations were selected via peer review. This guideline discusses endoscopic management of PFCs and makes recommendations on Indications for the procedure, pre-procedural preparations, optimal approach for drainage, procedural considerations (e.g., types of stent, advantages and disadvantages of plastic and metal stents, and accessories), adverse events of endoscopic intervention, and procedural quality issues. This guideline was reviewed by external experts and suggests best practices recommended based on the evidence available at the time of preparation. This will be revised as necessary to address advances and changes in technology and evidence obtained in clinical practice and future studies. (Gut Liver 2021;15:677-693)